{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:26:20Z","timestamp":1793067980552,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8050","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,2,13]]},"DOI":"10.1038\/s41586-024-08377-x","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:02:12Z","timestamp":1736334132000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Complex rearrangements fuel ER+ and HER2+ breast tumours"],"prefix":"10.1038","volume":"638","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-2099","authenticated-orcid":false,"given":"Kathleen E.","family":"Houlahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-0950","authenticated-orcid":false,"given":"Lise","family":"Mangiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-477X","authenticated-orcid":false,"given":"Cristina","family":"Sotomayor-Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina","family":"Adimoelja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongyeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-6224","authenticated-orcid":false,"given":"Aziz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia J.","family":"Pribus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-8355","authenticated-orcid":false,"given":"Jennifer L.","family":"Caswell-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-3802","authenticated-orcid":false,"given":"Christina","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"8377_CR1","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/cncr.34479","volume":"128","author":"KA Cronin","year":"2022","unstructured":"Cronin, K. A. et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer 128, 4251\u20134284 (2022).","journal-title":"Cancer"},{"key":"8377_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar, W. J. et al. NCCN Guidelines\u00ae Insights: breast cancer, version 4.2023. J. Natl Compr. Cancer Netw. 21, 594\u2013608 (2023).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"8377_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8377_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"8377_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399\u2013404 (2019).","journal-title":"Nature"},{"key":"8377_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085\u20132094 (2010).","journal-title":"Cancer Res."},{"key":"8377_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19291-x","volume":"11","author":"K-M Lee","year":"2020","unstructured":"Lee, K.-M. et al. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nat. Commun. 11, 5488 (2020).","journal-title":"Nat. Commun."},{"key":"8377_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"8377_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"8377_CR10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ccell.2022.10.021","volume":"40","author":"SH Strand","year":"2022","unstructured":"Strand, S. H. et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell 40, 1521\u20131536 (2022).","journal-title":"Cancer Cell"},{"key":"8377_CR11","unstructured":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020)."},{"key":"8377_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0431-1","volume":"15","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 15, 431 (2014).","journal-title":"Genome Biol."},{"key":"8377_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","volume":"52","author":"Z Hu","year":"2020","unstructured":"Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701\u2013708 (2020).","journal-title":"Nat. Genet."},{"key":"8377_CR14","doi-asserted-by":"crossref","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27 (2009).","DOI":"10.1200\/JCO.2008.18.1370"},{"key":"8377_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","volume":"95","author":"G Konecny","year":"2003","unstructured":"Konecny, G. et al. Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl Cancer Inst. 95, 142\u2013153 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"8377_CR16","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","volume":"51","author":"L Angus","year":"2019","unstructured":"Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450\u20131458 (2019).","journal-title":"Nat. Genet."},{"key":"8377_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","volume":"618","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2023","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature 618, 333\u2013341 (2023).","journal-title":"Nature"},{"key":"8377_CR18","doi-asserted-by":"publisher","first-page":"e0129876","DOI":"10.1371\/journal.pone.0129876","volume":"10","author":"R Vicario","year":"2015","unstructured":"Vicario, R. et al. Patterns of HER2 gene amplification and response to anti-HER2 therapies. PLoS ONE 10, e0129876 (2015).","journal-title":"PLoS ONE"},{"key":"8377_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984\u2013991 (2022).","journal-title":"Nature"},{"key":"8377_CR20","doi-asserted-by":"publisher","unstructured":"Everall, A. et al. Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.06.07.23290970 (2023).","DOI":"10.1101\/2023.06.07.23290970"},{"key":"8377_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41568-020-0241-6","volume":"20","author":"J Hausser","year":"2020","unstructured":"Hausser, J. & Alon, U. Tumour heterogeneity and the evolutionary trade-offs of cancer. Nat. Rev. Cancer 20, 247\u2013257 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"8377_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1090-z","volume":"21","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. Breast Cancer Res. 21, 14 (2019).","journal-title":"Breast Cancer Res."},{"key":"8377_CR23","doi-asserted-by":"crossref","unstructured":"Funnell, T. et al. Single-cell genomic variation induced by mutational processes in cancer. Nature 612, 106\u2013115 (2022).","DOI":"10.1038\/s41586-022-05249-0"},{"key":"8377_CR24","doi-asserted-by":"publisher","unstructured":"Caulfield, M. et al. National Genomic Research Library. Figshare https:\/\/doi.org\/10.6084\/M9.FIGSHARE.4530893.V7 (2020).","DOI":"10.6084\/M9.FIGSHARE.4530893.V7"},{"key":"8377_CR25","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.cell.2018.03.068","volume":"173","author":"SW Cho","year":"2018","unstructured":"Cho, S. W. et al. Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element. Cell 173, 1398\u20131412 (2018).","journal-title":"Cell"},{"key":"8377_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11908","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun. 7, 11908 (2016).","journal-title":"Nat. Commun."},{"key":"8377_CR27","doi-asserted-by":"publisher","first-page":"eabe6201","DOI":"10.1126\/scitranslmed.abe6201","volume":"13","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci. Transl. Med. 13, eabe6201 (2021).","journal-title":"Sci. Transl. Med."},{"key":"8377_CR28","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nat. Cancer 5, 1885\u20131901 (2024).","DOI":"10.1038\/s43018-024-00848-4"},{"key":"8377_CR29","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080\u20131088 (2023).","journal-title":"Nature"},{"key":"8377_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41586-023-06057-w","volume":"618","author":"JJ-K Lee","year":"2023","unstructured":"Lee, J. J.-K. et al. ER\u03b1-associated translocations underlie oncogene amplifications in breast cancer. Nature 618, 1024\u20131032 (2023).","journal-title":"Nature"},{"key":"8377_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.celrep.2015.08.066","volume":"13","author":"M Periyasamy","year":"2015","unstructured":"Periyasamy, M. et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep. 13, 108\u2013121 (2015).","journal-title":"Cell Rep."},{"key":"8377_CR32","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41588-023-01504-w","volume":"55","author":"JL McCann","year":"2023","unstructured":"McCann, J. L. et al. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer. Nat. Genet. 55, 1721\u20131734 (2023).","journal-title":"Nat. Genet."},{"key":"8377_CR33","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","volume":"11","author":"S Venkatesan","year":"2021","unstructured":"Venkatesan, S. et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 11, 2456\u20132473 (2021).","journal-title":"Cancer Discov."},{"key":"8377_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/ng.2955","volume":"46","author":"S Nik-Zainal","year":"2014","unstructured":"Nik-Zainal, S. et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487\u2013491 (2014).","journal-title":"Nat. Genet."},{"key":"8377_CR35","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1073\/pnas.1424869112","volume":"112","author":"DW Cescon","year":"2015","unstructured":"Cescon, D. W., Haibe-Kains, B. & Mak, T. W. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl Acad. Sci. USA 112, 2841\u20132846 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8377_CR36","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1126\/science.abg5784","volume":"373","author":"TD Martin","year":"2021","unstructured":"Martin, T. D. et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327\u20131335 (2021).","journal-title":"Science"},{"key":"8377_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","volume":"55","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2023","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. Genetic immune escape landscape in primary and metastatic cancer. Nat. Genet. 55, 820\u2013831 (2023).","journal-title":"Nat. Genet."},{"key":"8377_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865 (2021).","journal-title":"Cancer Cell"},{"key":"8377_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"8377_CR40","doi-asserted-by":"crossref","unstructured":"Houlahan, K. E. et al. Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Science 384, eadh8697 (2024).","DOI":"10.1126\/science.adh8697"},{"key":"8377_CR41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar, C. R. et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 7, 1098\u20131115 (2017).","journal-title":"Cancer Discov."},{"key":"8377_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","volume":"15","author":"L Zhai","year":"2018","unstructured":"Zhai, L. et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell. Mol. Immunol. 15, 447\u2013457 (2018).","journal-title":"Cell. Mol. Immunol."},{"key":"8377_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","volume":"600","author":"KL Hung","year":"2021","unstructured":"Hung, K. L. et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature 600, 731\u2013736 (2021).","journal-title":"Nature"},{"key":"8377_CR44","doi-asserted-by":"publisher","first-page":"e17548","DOI":"10.7554\/eLife.17548","volume":"5","author":"CT Stork","year":"2016","unstructured":"Stork, C. T. et al. Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage. Elife 5, e17548 (2016).","journal-title":"Elife"},{"key":"8377_CR45","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/1078-0432.CCR-22-2861","volume":"29","author":"PA Roelofs","year":"2023","unstructured":"Roelofs, P. A., Martens, J. W. M., Harris, R. S. & Span, P. N. Clinical implications of APOBEC3-mediated mutagenesis in breast cancer. Clin. Cancer Res. 29, 1658\u20131669 (2023).","journal-title":"Clin. Cancer Res."},{"key":"8377_CR46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08377-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08377-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08377-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T18:52:42Z","timestamp":1739386362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08377-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":46,"journal-issue":{"issue":"8050","published-print":{"date-parts":[[2025,2,13]]}},"alternative-id":["8377"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-08377-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unrelated to this work, the following interests are declared: S.P. has equity in Inocras; J.L.C.-J. holds grants from Effector Therapeutics, Novartis and QED Therapeutics; C.C. has\u00a0advised Bristol Myers Squibb, DeepCell, Genentech, NanoString, Pfizer and 3T Biosciences and has equity in 3T Biosciences,\u00a0DeepCell and Illumina. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}